Working… Menu

A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders (PROVIDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02354443
Recruitment Status : Terminated (Business decision)
First Posted : February 3, 2015
Results First Posted : October 10, 2018
Last Update Posted : October 10, 2018
Information provided by (Responsible Party):
Fate Therapeutics

Brief Summary:
The purpose of this study is to describe the safety profile of ProHema-CB as part of a single cord blood unit transplant after a myeloablative conditioning regimen in pediatric patients with inherited metabolic disorders. The safety profile will primarily be assessed by neutrophil engraftment.

Condition or disease Intervention/treatment Phase
Metabolic Disorders Biological: ProHema-CB Transplant Phase 1

Detailed Description:

This study is an open-label trial of the safety of a single cord blood transplant using ProHema-CB following busulfan/cyclophosphamide/ATG conditioning for pediatric patients with inherited metabolic disorders.

A maximum of 12 eligible male and female subjects (1 to 18 years old, inclusive) will be enrolled and treated in the trial at approximately 1 to 3 centers within the U.S.

All subjects will be admitted to the hospital, per institutional practice and will receive a conditioning regimen, after which they will receive a HLA-matched or partially matched ProHema -CB unit on Day 0.

They will receive study follow up assessments weekly following Day 0 through Day 100 and study visit Days 180, 270, 365 and 730.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Trial of a Single ProHema® CB Product as Part of Single Cord Blood Unit Transplant After Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients With Inherited Metabolic Disorders
Study Start Date : June 2015
Actual Primary Completion Date : December 2016
Actual Study Completion Date : February 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ProHema-CB
ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
Biological: ProHema-CB Transplant
ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.

Primary Outcome Measures :
  1. Safety Profile, Assessed Primarily by Neutrophil Engraftment [ Time Frame: Engraftment by Day 42 following study transplant procedure ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have a confirmed diagnosis of an inherited metabolic disorder (IMD) and be amenable to treatment by hematopoietic cell transplantation:

    • Mucopolysaccharidoses: Hurler Syndrome (MPS IH), MPS I-HS (Hurler-Scheie Syndrome), Hunter Syndrome (MPS II), Sanfilippo Syndrome (MPS III), or MPS VI (Maroteaux-Lamy syndrome) with early neurologic involvement and/or sensitization to enzyme replacement therapy (ERT); or
    • Leukodystrophies: Krabbe disease (Globoid Leukodystrophy), Metachromatic Leukodystrophy (MLD), Adrenoleukodystrophy (ALD and AMN); or
    • Other IMD with lysosomal storage disorder including glycoproteinoses (Alpha-Mannosidosis, Mucolipidosis II or I-Cell disease), sphingo- and other lipidoses (Sandhoff disease, Tay Sachs disease, Pelizaeus Merzbacher (PMD), Niemann-Pick disease, GM1 gangliosidosis, Wolman's disease.
  2. Male and female subjects aged 1 to 18 years, inclusive.
  3. Lack of 4 6/6 HLA matched non-carrier related UCB or 8/8 HLA A, B, C, DRß1 matched non-carrier related or 8/8 unrelated bone marrow donor; or donor not available within appropriate timeframe, as determined by the transplant physician.
  4. Availability of suitable primary and secondary umbilical cord blood (UCB) units.
  5. Adequate performance status, defined as:

    • Subjects ≥ 16 years: Karnofsky score ≥ 70%.
    • Subjects < 16 years: Lansky score ≥ 70%.
  6. Cardiac: Left ventricular ejection fraction at rest must be > 40%, or shortening fraction > 26%.
  7. Pulmonary:

    • Subjects > 10 years: DLCO (diffusion capacity) > 50% of predicted (corrected for hemoglobin)
    • FEV1, FVC > 50% of predicted; Note: If unable to perform pulmonary tests, then O2 saturation > 92% on room air.
  8. Renal: Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or GFR) > 70mL/min/1.73m2.
  9. Hepatic: Bilirubin ≤ 2.5 mg/dL (except in the case of Gilbert's syndrome, ongoing hemolytic anemia, or due to the primary IMD); and ALT, AST and Alkaline Phosphatase ≤ x 3 ULN (all elevations beyond the ULN must be secondary to the primary IMD and not a comorbid condition).
  10. Signed IRB approved Informed Consent Form (ICF).

Exclusion Criteria:

  1. Evidence of HIV infection or HIV positive serology.
  2. Current uncontrolled bacterial, viral or fungal infection (progression of clinical symptoms despite therapy).
  3. Requirement for continuous respiratory supportive therapy (e.g. ventilator). Patients on intermittent respiratory support should be discussed with the Sponsor.
  4. Active problems related to chronic aspiration.
  5. Uncontrolled seizures.
  6. Any active malignancy or myelodysplastic syndrome or any history of malignancy.
  7. Inability to give informed consent/assent or to comply with the requirements for care after allogeneic stem cell transplantation.
  8. Female subjects that are breastfeeding or with a positive pregnancy (HCG) test at Screening.
  9. Use of an investigational drug within 30 days prior to screening for the primary IMD.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02354443

Layout table for location information
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115-5450
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Fate Therapeutics
Layout table for investigator information
Study Director: Chris Storgard, MD Fate Therapeutics

Layout table for additonal information
Responsible Party: Fate Therapeutics Identifier: NCT02354443     History of Changes
Other Study ID Numbers: FT1050-05
First Posted: February 3, 2015    Key Record Dates
Results First Posted: October 10, 2018
Last Update Posted: October 10, 2018
Last Verified: February 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Diseases